Ruijian Medicine Secures RMB 260 Million Series C+ Financing Within a Month, Appoints Former Goldman Sachs and Morgan Stanley Executive Tim Ruan, and Files IPO Prospectus

On July 2, 2026, iRegene Therapeutics announced the completion ofRMB 260 million in Series C+ financing. This round of financing was led byLed by Chengdu Sci-Tech Innovation Investment, with participation from CCMC Capital, Wuxi Capital Group, Dingtai Xing, Xinjiye, and Hony Capitalco-invested by institutions such as , existing shareholdersYuanxi Haihe, Jinsha River Jointly Runpurun FengContinued Additional Investment.

iRegene Therapeutics completed in June 2026RMB 210 million in financing，Completing Two Rounds of Financing in Succession Within a Short Period, fully reflecting the continued recognition of iRegene Therapeutics by both new and existing investors. It also marksiRegene Therapeutics has entered a critical phase of transition from "technology platform validation" to "clinical value realization" and "accelerated capitalization."

iRegene Therapeutics’ core value is gradually shifting from platform potential toContinuous Delivery of the Clinical Pipeline。 

Completing two consecutive rounds of financing within a short period demonstrates the capital market’s strong recognition of the company:

First,Core Products Have Entered the Clinical Validation Phase in China and the United StatesThe Company is advancing the clinical development of multiple pipeline candidates in parallel in China and the United States. Its flagship candidate, NouvNeu001, has been granted Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA, demonstrating its international clinical value and regulatory recognition.

Second,Multi-Pipeline Strategy Is Establishing Clinical CertaintyIn addition to NouvNeu001, the Company is continuously advancing its pipeline candidates for multiple system atrophy (NouvNeu004) and its ophthalmology-focused NouvSight series, progressively evolving from a single-product model to a diversified portfolio of clinical-stage assets.

Third,Indications Focus on the Large Market Related to AgingiRegene Therapeutics focuses on Parkinson’s disease, retinal degenerative diseases, and metabolic decline, all of which are major disease areas with significant unmet clinical needs in the context of population aging, offering substantial long-term commercial potential.

Fourth,Capitalization Path Further Clarified. As multiple pipelines enter the stages of clinical development and data accumulation, the company has established the foundation for upgrading from an early-stage, technology-driven enterprise to a clinical-asset-driven, capital-market-valuable biotech company.

Core Products of iRegene Therapeutics NouvNeu001 It is a universal iPSC-derived dopaminergic neural precursor cell therapy product for Parkinson's disease, and it is also the company's core asset with the most advanced clinical progress and the highest attention from the capital market.

Currently, NouvNeu001 is advancing its clinical development in parallel in China and the United States. The product has been granted by the U.S. FDAFast Track EligibilityandAgainQualification for Advanced Therapy Medicinal Products (ATMPs), NouvNeu001 is advancing clinical development in both China and the United States, with its value proposition playing a critical role in validating the company’s R&D capabilities, clinical execution, regulatory strategy, and global development capabilities.

Beyond its core product, NouvNeu001, iRegene Therapeutics has established a robust pipeline of follow-on candidates with strong potential for clinical translation.

Developed by the Company for Multiple System Atrophy-Parkinsonian Type NouvNeu004 Having entered the clinical development stage signifies that the company possesses the capability to expand from Parkinson’s disease to adjacent indications within the field of neurodegenerative diseases.

In the field of ophthalmic diseases, the company has laid outNouvSight Series of pipelines. This pipeline possesses clear clinical value and commercialization potential, providing an important foundation for the company to establish a second growth curve in the future.

From the perspective of its pipeline structure, iRegene Therapeutics has initially formed a product portfolio comprising “core clinical assets + subsequent clinical pipeline + potential expansion into major indications.” This significantly enhances the stability of the company’s overall valuation, reduces risks associated with single projects, and strengthens its capabilities in subsequent financing, business development (BD) collaborations, and communication with the capital markets.

iRegene Therapeutics’ indication selection follows a clear long-term market logic. As global population aging accelerates, neurodegenerative diseases, ocular degenerative diseases, metabolic decline, and other age-related conditions are becoming major challenges for healthcare systems worldwide.For innovative pharmaceutical companies, age-related diseases not only represent significant unmet clinical needs but also a large healthcare market with strong long-term certainty.

iRegene Therapeutics focuses on aging-related indications, demonstrating the company's strategic foresight in its indication layout and forming a product portfolio with continuous development capabilities and long-term commercial value in the field of aging-related diseases.

This C+ round of financing introduced a diversified investor structure, further enhancing the certainty of the company’s future capitalization path.

The participation of institutions such as Chengdu Sci-Tech Innovation Investment, CCMC Capital, and Hony Capital helps enhance the company’s resource connectivity in the capital markets, subsequent financing, and potential capitalization pathways. Investments from industrial partners such as Dingtai Star and Xinjiye reflect the attention of industrial capital toward the company’s clinical pipeline and the future value of its products.

Meanwhile, existing shareholders Yuanxi Haihe and Jinshajiang United Runpuyuanfeng continued to increase their investments, demonstrating the sustained confidence of incumbent investors in the company.

Securing consecutive support from multiple professional investment institutions and industrial capital in the short term signifies that iRegene Therapeutics is gradually transitioning from an early-stage innovative enterprise to a more mature phase of cultivation within the capital market.

With the completion of this round of financing, iRegene Therapeutics has recruited executives from international capital markets.Mr. Tim Ruan (Ruan Tianshi), responsible for the company's subsequent capital operations. Mr. Ruan Tianshi previously served asGoldman Sachs Executive DirectorandVice President, Morgan Stanley, with experience in international investment banking, cross-border capital markets, innovative enterprise financing, and global investor communications.

The addition of Mr. Ruan Tianshi marks a significant upgrade to the management team at iRegene Therapeutics. His experience in international capital markets will help the company further refine its continuous financing strategy, capital market narrative, global investor relations, and the design of potential capitalization pathways.

With the addition of Mr. Ruan Tianshi, iRegene Therapeutics is establishing a management framework that synergistically advances “clinical development + industrialization + international capital markets,” providing stronger support for subsequent financing, business development (BD) collaborations, global expansion, and future capital market pathways.

Company management stated: "The completion of two consecutive financing rounds within a single month marks a significant milestone in the development of iRegene Therapeutics. We are deeply grateful for the recognition and support from both new and existing investors, and we also extend our sincere appreciation to Mr. Tim Ruan for joining the company. Moving forward, iRegene will leverage more efficient execution, a clearer capitalization pathway, and a more robust clinical development strategy to propel China’s original cell therapies onto the international stage."

Chengdu Sci-Tech Innovation Investment stated: “iRegene Therapeutics has built a systematic patent barrier around its ‘AI + Chemical Induction’ platform, with outstanding clinical data performance, positioning it at the forefront of the domestic industry. Chengdu Sci-Tech Innovation Investment led this round of financing, fully reflecting the strategic layout of state-owned capital in the frontier biomedical sector. Moving forward, we will continue to leverage the leading and empowering role of state-owned capital to provide long-term support for the company, helping iRegene Therapeutics achieve leapfrog development.”

Wuxi Capital Group stated: “Wuxi Capital Group is firmly committed to betting on a universal iPSC cell therapy platform. We highly recognize iRegene Therapeutics’ team’s capability in translational implementation, and we are confident that iRegene’s unique platform technology will steadily deliver clinical value and continue to solidify its position among the global first tier.”

CCMC stated, “Age-related diseases such as Parkinson’s disease face significant unmet clinical needs. CCMC is highly optimistic about the iPSC sector and the future development of iRegene Therapeutics. Leveraging the synergistic advantages of ‘investment + investment research + investment banking’ within China Securities Co., Ltd., CCMC will empower iRegene Therapeutics in the capital markets, with the expectation that iRegene Therapeutics’ products will benefit a broad patient population at an early stage.”

Dingtaixing stated: “iRegene Therapeutics’ dopaminergic neuron cell replacement therapy for Parkinson’s disease is at the forefront of global clinical development, demonstrating exceptional R&D capabilities and differentiated innovation. We firmly believe in the significant potential of the company’s pipeline and look forward to iRegene Therapeutics achieving continued breakthroughs, bringing innovative therapies to patients worldwide as soon as possible, and addressing major unmet clinical needs.”

With the completion of continuous financing, the advancement of multiple clinical pipelines, and the upgrading of its international capital markets team, iRegene Therapeutics is entering a new phase characterized by the realization of clinical value and accelerated capitalization, steadily progressing toward its goal of becoming a platform-type biotech company targeting the global market for age-related diseases.

Tap “Share”、“Like"and"Viewing", charge me up a bit~